Abstract:
The present invention is directed to compounds of formula (I) (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.
Abstract:
The present invention is directed to compounds of formula (I) (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.
Abstract:
The present invention is directed to compounds of formula (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.
Abstract:
The present invention is directed to compounds of formula (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.
Abstract:
La presente invencion se dirige a los compuestos de la formula (I) en donde los variables, W, X, Y, D, A, n, R1, R2 y R9 son como se definen en la descripcion.
Abstract:
Novel compounds which are selective dopamine agonists are useful for treating disorders characterized by abnormal dopamine levels, such as Parkinson's Disease, as well as cardiovascular disorders.
Abstract:
Disclosed are substituted imidazole and oxazole compounds of formula (I), wherein A is O or -N(R3), D is O or -N(R4), and the remaining substituents are as defined in the specification, and compositions comprising them. The compounds are useful for treating disorders caused by or exacerbated by vanilloid receptor activity, such as pain, bladder overactivity, and urinary incontinence.
Abstract:
The present invention is directed to compounds of formula (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.
Abstract:
The present invention is directed to compounds of formula (I) wherein variables W, X, Y, D, A, n, R1, R2 and R9 are as defined in the description.
Abstract:
Compounds of formula (I) wherein R3, R7, R9 and L are defined in the description are TRPV1 antagonists that exhibit low inhibitory activity against CYP3A4. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.